ArticleEuropean journal of medical research2025

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer.

Kaichen Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.